Abstract
Gilead Sciences and Merck & Co. will collaborate to develop a long-acting HIV treatment that combines Gilead’s capsid inhibitor lenacapavir with Merck’s islatravir, a nucleoside reverse transcriptase translocation inhibitor. The molecules are being studied separately in late-stage trials to treat or prevent HIV. Both have long half-lives and robust virus-suppressing activity at low doses. The goal is to replace the daily regimen of pills taken by people with HIV with one pill that is taken every few months.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.